冠城大通(600067.SH):第二期員工持股計劃即將屆滿
格隆匯7月9日丨冠城大通(600067.SH)公佈,第二期員工持股計劃的存續期為67個月,即2016年6月8日至2022年1月7日止。存續期滿後自行終止。
第二期員工持股計劃鎖定期為12個月,自公司公吿標的股票登記過户至資產管理計劃名下之日起算,即2016年12月8日至2017年12月7日。截至目前,該股票鎖定期已經結束。在鎖定期屆滿後,第二期員工持股計劃將根據市場的情況決定何時賣出股票。當員工持股計劃所持資產均為貨幣資金時可提前終止。
截至公吿日,第二期員工持股計劃持有公司股票3812.245萬股,佔公司現有總股本比例為2.55%,持股數量未發生變動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.